<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">s13063-014-0528-6</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Study protocol</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>Erythropoietin in traumatic brain injury: study protocol for a randomised controlled
               trial
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Nichol</span>
               <span tagx="fnm">Alistair</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="alistair.nichol@monash.edu">alistair.nichol@monash.edu</a>
            </li>
            <li tagx="au">
               <span tagx="snm">French</span>
               <span tagx="fnm">Craig</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="craig.french@wh.org.au">craig.french@wh.org.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Little</span>
               <span tagx="fnm">Lorraine</span>
               <span tagx="insr"></span>
               <a href="lorraine.little@monash.edu">lorraine.little@monash.edu</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Presneill</span>
               <span tagx="fnm">Jeffrey</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="intensive@fastmail.com.au">intensive@fastmail.com.au</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Cooper</span>
               <span tagx="mnm">James</span>
               <span tagx="fnm">D</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="jamie.cooper@monash.edu">jamie.cooper@monash.edu</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Haddad</span>
               <span tagx="fnm">Samir</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="haddads55@yahoo.com">haddads55@yahoo.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Duranteau</span>
               <span tagx="fnm">Jacques</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="jacques.duranteau@bct.aphp.fr">jacques.duranteau@bct.aphp.fr</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Huet</span>
               <span tagx="fnm">Olivier</span>
               <span tagx="insr"></span>
               <a href="olivier.huet@chu-brest.fr">olivier.huet@chu-brest.fr</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Skrifvars</span>
               <span tagx="fnm">Markus</span>
               <span tagx="insr"></span>
               <a href="Markus.Skrifvars@hus.fi">Markus.Skrifvars@hus.fi</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Arabi</span>
               <span tagx="fnm">Yaseen</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="Arabi@NGHA.MED.SA">Arabi@NGHA.MED.SA</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Bellomo</span>
               <span tagx="fnm">Rinaldo</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="rinaldo.bellomo@austin.org.au">rinaldo.bellomo@austin.org.au</a>
            </li>
            <li tagx="au">
               <div tagx="cnm">On behalf of the EPO-TBI Investigators and the Australian and New Zealand Intensive
                  Care Society Clinical Trials Group
               </div>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>Australian and New Zealand Intensive Care Research Centre, School of Public Health
                  and Preventive Medicine, Monash University, 99 Commercial Road, Melbourne 3004, Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Intensive Care Medicine, The Alfred, Commercial Road, Melbourne 3004,
                  Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Anaesthesia and Intensive Care Medicine, St Vincent’s University Hospital,
                  Elm Park, Dublin 4, Ireland
               </p>
            </li>
            <li tagx="ins">
               <p>School of Medicine and Medical Sciences, University College Dublin, Elm Park, Dublin
                  4, Ireland
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Intensive Care, Western Health, Gordon Street, Footscray 3011, Australia</p>
            </li>
            <li tagx="ins">
               <p>Department of Medicine North West Academic Centre, The University of Melbourne, Grattan
                  Street, Parkville 3052, Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Intensive Care, Mater Health Services, Raymond Terrace, South Brisbane
                  4101, Australia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Intensive Care, King Abdulaziz Medical City, Riyadh 11426, Kingdom of
                  Saudi Arabia
               </p>
            </li>
            <li tagx="ins">
               <p>Service d’Anesthésie-Réanimation, Hôpitaux universitaires Paris Sud, Assistance Publique
                  des Hôpitaux de Paris, Hôpital de Bicêtre, 78, rue du Général Leclerc, Le Kremlin
                  Bicêtre, 94275, France
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Anesthesiology and Intensive Care Medicine, Centre Hospitalier Universitaire
                  La Cavale Blanche Université de Bretagne Ouest, Brest Cedex, 29609, France
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital,
                  Helsinki, FIN-00029, Finland
               </p>
            </li>
            <li tagx="ins">
               <p>Intensive Care Department, College of Medicine King Saud Bin Abdulaziz University
                  for Health Sciences and King Abdullah International Medical Research Center, Riyadh
                  11426, Kingdom of Saudi Arabia
               </p>
            </li>
            <li tagx="ins">
               <p>Department of Intensive Care, Austin Health, Studley Road, Heidelberg 3084, Australia</p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">39</span>
         <a href="http://www.trialsjournal.com/content/16/1/39">http://www.trialsjournal.com/content/16/1/39</a>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">10.1186/s13063-014-0528-6</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">5</span>
               <span tagx="month">9</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">19</span>
               <span tagx="month">12</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">8</span>
               <span tagx="month">2</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Nichol et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <ul tagx="kwdg">
         <li tagx="kwd">Traumatic brain injury</li>
         <li tagx="kwd">Erythropoietin</li>
         <li tagx="kwd">Outcome</li>
         <li tagx="kwd">Critical care</li>
         <li tagx="kwd">Randomised controlled trials</li>
      </ul>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>Traumatic brain injury is a leading cause of death and disability worldwide. Laboratory
                  and clinical studies demonstrate a possible beneficial effect of erythropoietin in
                  improving outcomes in the traumatic brain injury cohort. However, there are concerns
                  regarding the association of erythropoietin and thrombosis in the critically ill.
                  A large-scale, multi-centre, blinded, parallel-group, placebo-controlled, randomised
                  trial is currently underway to address this hypothesis.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods/design</h3>
               </div>
               <p>The erythropoietin in traumatic brain injury trial is a stratified prospective, multi-centre,
                  randomised, blinded, parallel-group, placebo-controlled phase III trial. It aims to
                  determine whether the administration of erythropoietin compared to placebo improves
                  neurological outcome in patients with moderate or severe traumatic brain injury at
                  six months after injury. The trial is designed to recruit 606 patients between 15
                  and 65 years of age with severe (Glasgow Coma Score: 3 to 8) or moderate (Glasgow
                  Coma Score: 9 to 12) traumatic brain injury in Australia, New Zealand, Kingdom of
                  Saudi Arabia, France, Finland, Germany and Ireland.
               </p>
               <p>Trial patients will receive either subcutaneous erythropoietin or placebo within 24
                  hours of injury, and weekly thereafter for up to three doses during the intensive
                  care unit admission. The primary outcome will be the combined proportion of unfavourable
                  neurological outcomes at six months: severe disability or death. Secondary outcomes
                  will include the rate of proximal deep venous thrombosis detected by compression Doppler
                  ultrasound, six-month mortality, the proportion of patients with composite vascular
                  events (deep venous thrombosis, pulmonary embolism, myocardial infarction, cardiac
                  arrest and cerebrovascular events) at six months and quality of life with health economic
                  evaluations.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Discussion</h3>
               </div>
               <p>When completed, the trial aims to provide evidence on the efficacy and safety of erythropoietin
                  in traumatic brain injury patients, and to provide clear guidance for clinicians in
                  their management of this devastating condition.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Trial registration</h3>
               </div>
               <p>Australian New Zealand Clinical Trials registry: 
                  <a href="ACTRN12609000827235">ACTRN12609000827235</a> (registered on 22 September 2009).
               </p>
               <p>Clinicaltrials.gov: 
                  <a href="NCT00987454">NCT00987454</a> (registered on 29 September 2009). European Drug Regulatory Authorities Clinical
                  Trials: 2011-005235-22 (registered on 18 January 2012).
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <p>Traumatic brain injury (TBI) is a devastating condition which affects close to 1,000
         people each year in Australia, causes extensive long-term disability and suffering,
         which subsequently results in approximately 1 billion Australian dollars in lifetimes
         costs per year 
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>. Disability follows from primary and secondary brain injury. Attenuation of secondary
         brain injury (decreasing the additional injury due to the inflammatory, excitotoxic
         and apoptotic response to trauma) is possible 
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>. Erythropoietin (EPO) is a glycoprotein hormone with pleiotropic cytokine-like effects
         
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>. EPO has effects, independent of those on erythropoiesis, which are relevant to patients
         who have had a TBI. They include anti-apoptotic activity and protective neurological
         effects in the presence of hypoxia and ischaemia 
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span>. A neuroprotective effect of EPO has been demonstrated in animal models of TBI 
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">6</span>
         </span>. A large, multi-centre, randomised controlled trial (RCT) demonstrated that EPO improved
         survival in a retrospectively identified trauma cohort 
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span>. A subsequent large RCT by the same group found that while EPO did not reduce transfusion
         rates, in a prospectively identified trauma cohort (including TBI) EPO significantly
         decreased 29-day mortality compared to a placebo (3.5 versus 6.6%) 
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>. Additional observational studies and one very small RCT support the hypothesis that
         EPO may improve neurological outcomes after TBI 
         <span tagx="abbrgrp">
            <span tagx="abbr">9</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">10</span>
         </span>. However, many concerns have been raised about the ability of EPO to increase the
         risk of venous thromboembolism (VTE) 
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">12</span>
         </span>. The United States Food and Drug Administration recently added a black box warning
         regarding this risk on EPO preparations. However, it is worth noting that the largest
         trial in the critically ill to date demonstrates a clear survival advantage in traumatically
         injured patients who are generally most vulnerable to VTE complications.
      </p>
      <p>The question of whether the administration of EPO benefits patients with TBI remains
         unanswered. To address this evidence gap we are undertaking a large multi-centre,
         blinded, parallel-group, placebo-controlled randomised trial comparing the administration
         of EPO with a placebo. This trial will be sufficiently powered to detect clinically
         relevant differences in neurological outcomes measured by the eight-level Extended
         Glasgow Outcome Scale (GOSE) 
         <span tagx="abbrgrp">
            <span tagx="abbr">13</span>
         </span> at six months following injury.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Methods/design</h2>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Trial design and outcomes</h3>
         </div>
         <p>The erythropoietin in traumatic brain injury (EPO-TBI) trial is a stratified prospective,
            multi-centre, randomised, blinded, parallel-group, placebo-controlled phase III trial.
            It aims to determine whether the administration of EPO compared to a placebo improves
            neurological outcome in patients with moderate or severe TBI at six months after injury.
            The trial is designed to recruit 606 patients between 15 and 65 years of age with
            severe (Glasgow Coma Score(GCS): 3 to 8) or moderate (GCS: 9 to 12) TBI in Australia,
            New Zealand, Kingdom of Saudi Arabia, France, Finland, Germany and Ireland.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Participants</h3>
         </div>
         <p>Patients aged between 15 and 65 years with non-penetrating moderate or severe TBI
            will be eligible for this trial. These criteria were designed to exclude patients
            with unsurvivable neurological injury, patients at a high risk of VTE and those who
            would be exposed to additional risk due to the trial drug.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Inclusion criteria</h3>
         </div>
         <p>Patients with non-penetrating moderate (Glasgow Coma Score (GCS) 9–12) or severe (GCS
            3–8) traumatic brain injury admitted to an ICU who:
         </p>
         <p>1. Are ≥15 to ≤65 years of age
            <sup>a</sup>
         </p>
         <p>2. Are &lt;24 hours since primary traumatic injury</p>
         <p>3. Are expected to stay ≥48 hours</p>
         <p>4. Have a haemoglobin not exceeding the upper limit of the applicable normal reference
            range in clinical use at the treating institution
            <sup>b</sup>
         </p>
         <p>5. Have written informed consent from legal surrogate</p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Exclusion criteria</h3>
         </div>
         <p>Patients are excluded from the study if any of the following criteria apply
            <sup>c</sup>:
         </p>
         <p>1. GCS = 3 and fixed dilated pupils</p>
         <p>2. History of deep vein thrombosis, pulmonary embolism or other thromboembolic event</p>
         <p>3. A chronic hypercoagulable disorder, including known malignancy</p>
         <p>4. Treatment with erythropoietin in the last 30 days</p>
         <p>5. First dose of study drug unable to be given within 24 hours of primary injury</p>
         <p>6. Pregnancy or lactation or 3 months post-partum</p>
         <p>7. Uncontrolled hypertension (systolic blood pressure &gt;200 mmHg or diastolic blood
            pressure &gt;110 mmHg)
         </p>
         <p>8. Acute myocardial infarct within the past 12 months</p>
         <p>9. Past history of epilepsy with seizures in past 3 months</p>
         <p>10. Expected to die imminently (&lt;24 hours)</p>
         <p>11. Inability to perform lower limb ultrasounds</p>
         <p>12. Known sensitivity to mammalian cell-derived products</p>
         <p>13. Hypersensitivity to the active substance or to any of the additives</p>
         <p>14. Pure red cell aplasia</p>
         <p>15. End-stage renal failure (receives chronic dialysis)</p>
         <p>16. Severe pre-existing physical or mental disability or severe co-morbidity that
            may interfere with the assessment of outcome
         </p>
         <p>17. Spinal cord injury</p>
         <p>18. Treatment with any investigational drug within 30 days before enrolment</p>
         <p>19. The treating physician believes it is not in the best interests of the patient
            to be randomised to this trial
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Outcomes measures</h3>
         </div>
         <p>The primary outcome of this trial is the patients’ neurological status at six months,
            summarized as a binary midpoint reduction of their eight-level Extended Glasgow Outcome
            Scale (GOSE) score, defined as favourable (GOSE score: 5 to 8; moderate disability
            and good recovery) or unfavourable (GOSE score: 1 to 4; death and severe disability).
         </p>
         <p>Secondary outcomes include:</p>
         <p>1. Neurological status at six months summarized by the eight-level GOSE</p>
         <p>2. Quality of life assessment using the Short Form 12 (SF-12) 
            <span tagx="abbrgrp">
               <span tagx="abbr">14</span>
            </span> and EuroQoL-5D (EQ-5D) 
            <span tagx="abbrgrp">
               <span tagx="abbr">15</span>
            </span> at six months
         </p>
         <p>3. Mortality at six months</p>
         <p>4. Proximal deep venous thrombosis (DVT) detected by ultrasound</p>
         <p>5. Occurrence of a thrombotic vascular event (including DVT, pulmonary embolism, myocardial
            infarction, cardiac arrest and cerebrovascular events) at six months. The definitions
            for these events are previously reported 
            <span tagx="abbrgrp">
               <span tagx="abbr">16</span>
            </span>
         </p>
         <p>6. Resource use and costs at six months</p>
         <p>7. Incremental cost effectiveness</p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Trial interventions</h3>
         </div>
         <p>The intervention to be examined in this trial is the subcutaneous administration of
            erythropoietin 40,000 International Units (IU) compared to a placebo (0.9% saline).
         </p>
         <p>A summary of the trial interventions and follow up schedule is provided in Figure 
            <div tagx="figr">1</div>.
            
         </p>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 1</p>
            </div>
            <caption>
               <p>Summary of trial treatment and follow up schedule. </p>
            </caption>
            <div tagx="text">
               <p>
                  <b>Summary of trial treatment and follow up schedule.</b> The baseline ultrasound may be performed before or at least within 48 hours after
                  the first dose administration. EPO, Erythropoietin (Epoetin alfa) 40,000 IU or normal
                  saline placebo; US, Ultrasound.
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Investigational product</h3>
         </div>
         <p>The trial drug is Epoetin alfa 40,000 IU in a pre-filled syringe, manufactured by
            Janssen-Cilag Pty Ltd, or the placebo sodium chloride 0.9. The trial drug will be
            administered by subcutaneous injection.
         </p>
         <p>For patients randomised to the treatment arm, an unblinded nurse will administer the
            full contents of the Epoetin alfa 40,000 IU pre-filled syringe to the patient. For
            patients randomised to the placebo arm, an unblinded nurse will administer 1 mL from
            a sodium chloride 0.9% 10 mL ampoule.
         </p>
         <p>The first dose will be given within 24 hours of the estimated time of TBI, and then
            weekly for up to two more doses (on trial days eight and 15). The trial drug will
            only be administered to patients during the ICU admission. If the patient is discharged
            to the general ward (before trial day eight or before day 15) they will not receive
            any further doses of trial drug. Patients readmitted to ICU during the same hospital
            stay will not receive any further doses of the trial drug.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Variable haemoglobin threshold for dosing to reduce the risk of thromboembolic complications</h3>
         </div>
         <p>Previous trials examining the long-term use of EPO in renal failure 
            <span tagx="abbrgrp">
               <span tagx="abbr">12</span>
            </span> and cancer 
            <span tagx="abbrgrp">
               <span tagx="abbr">11</span>
            </span> patients targeting haemoglobin (Hb) concentrations above 120 g/L (12 g/dL) have demonstrated
            an increased risk of thromboembolic complications. Observational studies also demonstrate
            that the Hb concentration in critically ill patients falls rapidly in the first 72
            hours of admission 
            <span tagx="abbrgrp">
               <span tagx="abbr">17</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">18</span>
            </span>. A dosing structure based on Hb concentration was developed to address the known
            risks of thromboembolic complications associated with EPO use: the first dose of trial
            drug is administered only if the haemoglobin (Hb) concentration is less than the upper
            limit of the applicable normal reference range in clinical use at the treating institution;
            the second and third doses are administered only if the Hb concentration is &lt;120 g/L
            (12 g/dL).
         </p>
         <p>The second (trial day eight) and third (trial day 15) doses may be given the day before
            or after dosing day, so the trial drug is prepared in pharmacy business hours. The
            weekly dose will not be administered if the patient’s pre-medication Hb is ≥120 g/L
            (12 g/dL); the trial drug will be temporarily withheld for that dose. The patient
            will be assessed on the next scheduled dosing day. If their Hb is &lt;120 g/L (12 g/dL),
            the dose may be given if the patient is still in the ICU and has not met the permanent
            withholding criteria.
         </p>
         <p>At Johannes Gutenberg-Universtität, Mainz Germany an additional temporary trial drug
            withholding criterion applies. The weekly dose will not be administered if the patient
            has a refractory high blood pressure; the trial drug will be withheld for that dose,
            and the patient will be assessed on the next scheduled dosing day. No further doses
            will be administered if the patient has met any permanent withholding criteria.
         </p>
         <p>Permanent withholding criteria:</p>
         <p>1. Development of proximal deep venous thrombosis</p>
         <p>2. Development of pulmonary embolism</p>
         <p>3. Any other thrombotic event</p>
         <p>4. Acute myocardial infarction</p>
         <p>5. Cardiac arrest or ventricular fibrillation</p>
         <p>6. Cerebrovascular accident</p>
         <p>7. Any serious adverse event or protocol deviation where, in the attending physician’s
            opinion, the patient should not receive any further doses of the trial drug
         </p>
         <p>8. Consent has been withdrawn or consent to continue has not been granted</p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Management of traumatic brain injury</h3>
         </div>
         <p>The ICU medical team will have full independent control of patient management, however
            the trial management committee request that standardised TBI clinical practice follows
            Brain Trauma Foundation 
            <span tagx="abbrgrp">
               <span tagx="abbr">19</span>
            </span> guidelines.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Compression Doppler ultrasound</h3>
         </div>
         <p>Critically ill patients are at risk of VTE complications. Previous studies, which
            did not specifically screen for VTE, have demonstrated an association of EPO with
            increased rates of VTE. The true risk is unknown in the critically ill as clinical
            examination has severe limitations, and many clinically undetected VTE complications
            are revealed when prospective screening is performed. The risk of VTE in the traumatically
            injured patients is potentially further elevated, as concerns regarding intracerebral
            haemorrhage frequently discourage clinicians giving pharmaceutical agents (low molecular
            weight heparins) to mitigate this risk. Therefore, to address this potential and largely
            unknown risk of EPO in the traumatically injured patients, we designed a prospective
            VTE screening algorithm. Bilateral compression Doppler ultrasound of the lower extremities
            will be performed to monitor for proximal DVT at baseline (before the first dose if
            possible, or at least within 48 hours after the first dose administration) then twice
            weekly after each dose of the trial drug for three weeks or up to ICU discharge, whichever
            occurs first. The procedure for the ultrasound was standardised, with evaluation of
            the following veins: common femoral, proximal femoral, mid femoral, distal femoral,
            popliteal and trifurcation.
         </p>
         <p>Up to six scheduled twice weekly ultrasounds will be performed if the patient is an
            inpatient in the ICU for longer than three weeks. No further scheduled twice weekly
            ultrasounds are required beyond trial day 21.
         </p>
         <p>If the patient meets a temporary or permanent withholding criteria and remains in
            the ICU, the twice weekly compression Doppler ultrasounds are performed up to trial
            day 21 or ICU discharge, whichever occurs first.
         </p>
         <p>Bilateral compression Doppler ultrasounds will be performed on the general ward if
            the patient has been transferred after a dose of the trial drug and before a scheduled
            ultrasound has been performed. This will ensure at least one bilateral compression
            Doppler ultrasound will be performed after each dose of the trial drug.
         </p>
         <p>The site treating clinicians outside the ICU (known variously by names such as Parent
            Unit, Admitting Unit or Attending Medical Service) are required to notify the site
            researchers of any occurrences of VTE as soon as it is diagnosed.
         </p>
         <p>Additional bilateral compression Doppler ultrasounds will be performed on suspicion
            of DVT or pulmonary embolism. The treating clinician may therefore take additional
            measures to reduce the risk of complications from any identified thrombosis. We anticipate
            that this algorithm will mitigate any additional risk that could be posed by the use
            of EPO in this cohort.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Randomisation and allocation concealment</h3>
         </div>
         <p>Concealed randomisation will be performed via a web-based system that includes block
            randomisation at each site. Treatment allocation will be stratified by site and also
            by the severity of TBI at randomisation (moderate (GCS: 9 to 12) or severe (GCS: 3
            to 8).
         </p>
         <p>Bias will be minimised by concealed random allocation by the use of a robust primary
            outcome minimally susceptible to ascertainment bias, and by blinded assessment of
            the primary outcome by a trained outcome assessor at the coordinating centre (Australia
            and New Zealand) or by trained, blinded outcome assessors in each country in Europe
            and the Kingdom of Saudi Arabia.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Blinding plan</h3>
         </div>
         <p>Site personnel will be blinded to treatment allocation. For the efficient conduct
            of the trial the site pharmacists, site unblinded dosing nurses and the pharmacists
            at the central pharmacy in France (Clinical Trial Department of the Pharmaceutical
            Establishment of Assistance Publique-Hôpitaux de Paris) will be unblinded to treatment
            assignment.
         </p>
         <p>Staff at the coordinating centre will be blinded to treatment allocation, except for
            an unblinded project officer (Appendix 1) and designee, the analyst programmers responsible
            for the web-based data management system and a nominated statistician who will supervise
            data extraction from the database for interim and final analyses. The French management
            team will be blinded to treatment assignment.
         </p>
         <p>Following patient randomisation by the site investigator or designee, an unblinded
            trial pharmacist will dispense the trial drug in a tamperproof sealed opaque box (Figure 
            <div tagx="figr">2</div>) to blind the treatment assignment. The box may only be opened by the site’s designated
            unblinded trial dosing nurse. For patients who receive the active treatment the sealed
            box will consist of one Epoetin alfa 40,000 IU pre-filled syringe labelled with direction
            for use ‘Inject 1 ml subcutaneously over at least 1 minute’. For patients who receive
            the placebo the sealed box will consist of one sodium chloride 0.9% 10 mL ampoule
            labelled with direction for use ‘Inject 1 ml subcutaneously over at least 1 minute’.
            
         </p>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 2</p>
            </div>
            <caption>
               <p>Blinded tamperproof sealed box. </p>
            </caption>
            <div tagx="text">
               <p>
                  <b>Blinded tamperproof sealed box.</b>
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
         <p>For safety reasons, unblinded dosing nurses will be allocated in each research site
            to administer EPO or placebo doses discreetly, with a screen around the patient bed
            area. The trial drug or placebo dose may be checked with a second unblinded nurse
            if required to comply with local hospital regulations. After dose administration the
            unblinded dosing nurse will discard the used trial drug in such a manner as to maintain
            the blind. These unblinded dosing nurses will have access to the unblinded trial pharmacist.
            Unblinded dosing nurses will not be involved in the care of a trial patient and may
            not discuss trial drug treatment with research staff or other members of the ICU or
            hospital staff.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Data collection and management</h3>
         </div>
         <p>All data will be collected by trained staff at each trial site using a paper source
            document developed by the coordinating centre. Data will then be entered into a web
            database designed by the trial project manager in collaboration with the Monash University
            Monash University Clinical Informatics and Data Management Unit. Data queries will
            be automatically generated via the electronic data collection database, and at monitoring
            by the trial project manager or the clinical research associate (in France).
         </p>
         <p>Randomised patients will be followed up to death or six months post-randomisation
            (whichever occurs first). Data collection will be restricted primarily to those variables
            necessary to define clinical patient characteristics including: baseline demographics,
            primary diagnoses, physiological parameters, Acute Physiology and Chronic Health Evaluation
            II (APACHE II), Injury Severity Score (ISS), Abbreviated Injury Severity Score (AIS)
            and Computed Tomography Brain Marshall Score 
            <span tagx="abbrgrp">
               <span tagx="abbr">20</span>
            </span>, diagnostic interventions, therapeutic interventions, and documentation of deaths
            and other serious adverse events (SAE).
         </p>
         <p>To prepare for the six-month follow-up assessment, patients and/or their legal surrogate
            will be asked to provide three possible points of contact (home and close family contact
            details) to the research staff prior to hospital discharge. Full protocol data will
            be collected in all patients including those excluded at any stage. Patients who are
            alive at six months after randomisation (or their carer or proxy if more appropriate)
            will be interviewed by a trained outcome assessor from Monash University for patients
            in Australia and New Zealand, or trained outcome assessors in each country in Europe
            and the Kingdom of Saudi Arabia. The regional assessors will use a standardized structured
            telephone questionnaire 
            <span tagx="abbrgrp">
               <span tagx="abbr">21</span>
            </span> to measure the eight-level GOSE 
            <span tagx="abbrgrp">
               <span tagx="abbr">13</span>
            </span>. Neurological outcomes will then be defined as favourable (GOSE score: 5 to 8; moderate
            disability and good recovery) or unfavourable (GOSE score: 1 to 4; death and severe
            disability). Patients subsequently withdrawn for any reason (DVT, pulmonary embolism,
            myocardial infarction, cerebrovascular accident, cardiac arrest, or an SAE) or who
            did not receive the trial drug will be followed up on, according to the study follow-up
            schedule, and analysed according to the modified intention-to-treat principle 
            <span tagx="abbrgrp">
               <span tagx="abbr">22</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
            </span>.
         </p>
         <p>Trained outcome assessors (Appendix 2) will collect data for surviving patients at
            six months for quality of life assessment using the EQ-5D 
            <span tagx="abbrgrp">
               <span tagx="abbr">15</span>
            </span> questionnaire and the SF-12 
            <span tagx="abbrgrp">
               <span tagx="abbr">14</span>
            </span> questionnaire. If the patient is not well enough or not available to complete the
            questionnaires, the SF-12 questionnaire will not be completed 
            <span tagx="abbrgrp">
               <span tagx="abbr">24</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">25</span>
            </span> and quality of life will not be assessed for that patient.
         </p>
         <p>Data will be collected from surviving patients at six months for cost effectiveness
            analysis, with utilities calculated using the EQ-5D 
            <span tagx="abbrgrp">
               <span tagx="abbr">15</span>
            </span> results, and costs will be calculated based on ICU, acute and post-acute care resource
            use. If the patient is not well enough or not available to complete the EQ-5D the
            patient’s proxy will be asked to complete it for the patient.
         </p>
         <p>The outcome assessments will be monitored by an experienced and trained outcome assessor
            at Monash University.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Ethical issues</h3>
         </div>
         <p>This is a trial conducted in patients who are unconscious and unable to consent to
            participation, therefore the patient’s legal surrogate will be approached to provide
            consent for the patient. Patients who recover sufficient cognition to understand the
            explanation of the trial will additionally be asked to consent to continue in the
            trial if this is required under the ethics committee approval conditions.
         </p>
         <p>In France patients may be enrolled under an Emergency clause. Informed consent was
            obtained from each patient’s legal surrogate for participation in the trial.
         </p>
         <p>Approval for this protocol has been obtained from appropriate regulatory authorities,
            and from participating hospitals’ human research ethics committees. The list of responsible
            ethics committees is provided as an Additional file 
            <div tagx="supplr">1</div>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Sample size and power</h3>
         </div>
         <p>The estimated rate of unfavourable neurological outcome (death and severe disability)
            in Australian and New Zealand patients with moderate and severe TBI 
            <span tagx="abbrgrp">
               <span tagx="abbr">26</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">27</span>
            </span> is approximately 50%.
         </p>
         <p>A trial of 574 patients will have a 90% power at an alpha of 0.05 to detect a 14%
            absolute risk reduction (50 versus 36%) and 80% power to detect a 12% (50 versus 38%)
            absolute risk reduction in unfavourable neurological outcome. A trial of this size
            was also estimated to have 80% power to detect a 9% absolute risk increase in proximal
            lower limb DVT from an assumed baseline proportion of 18% (50% increase in relative
            risk) at a one-sided alpha of 0.05. Allowing for a 5% withdrawal and loss to follow-up
            rate, we will recruit 606 patients to prevent any loss of power and to conduct an
            adequately powered modified intention-to-treat analysis 
            <span tagx="abbrgrp">
               <span tagx="abbr">22</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
            </span>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Statistical analysis</h3>
         </div>
         <p>Independent senior statisticians at Monash University Department of Epidemiology and
            Preventive Medicine will perform data analyses following a detailed statistical analysis
            plan, which will be published separately in the journal 
            <i>Trials</i>.
         </p>
         <p>A modified intention-to-treat analysis will be performed based on all randomly assigned
            patients, except those withdrawing consent for use of all trial data, those not fulfilling
            inclusion criteria and those who never receive the intervention 
            <span tagx="abbrgrp">
               <span tagx="abbr">22</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
            </span>. Baseline variables will be summarised using descriptive statistics. The trial primary
            outcome will be compared between treatments with an unadjusted risk ratio and 95%
            confidence interval. Sensitivity analyses will be performed using logistic regression
            adjusting for stratification factors, pre-specified prognostic factors and any other
            baseline covariates exhibiting substantial imbalance between randomisation arms. Furthermore,
            a proportional odds cumulative logit model 
            <span tagx="abbrgrp">
               <span tagx="abbr">28</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">29</span>
            </span>, adjusting for relevant covariates, will be applied to the eight-level vector of
            the six-month GOSE score.
         </p>
         <p>Other secondary analyses, including assessment of outcomes according to actual treatment
            received, quality of life assessment, mortality at hospital discharge and six months
            and incidence of adverse events (AE), will be compared between treatment groups using
            unadjusted and adjusted logistic regression and log-binomial regression. Pre-specified
            subgroup analyses will be obtained using interaction terms in logistic regression
            models. Adjusted effect estimates of the EPO intervention, derived from logistic and
            proportional odds ordinal logistic models, will be reported as adjusted risk ratios
            averaged over the remaining covariates, as recently recommended 
            <span tagx="abbrgrp">
               <span tagx="abbr">30</span>
            </span>-
            <span tagx="abbrgrp">
               <span tagx="abbr">32</span>
            </span>. Time-to-event analyses will be undertaken using Kaplan-Meier curves, as well as
            unadjusted and adjusted Cox proportional hazards regression models.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Data and safety monitoring</h3>
         </div>
         <p>An independent Data Safety and Monitoring Committee (DSMC) comprising of experts in
            clinical trials, biostatistics and intensive care, will monitor SAEs throughout the
            trial, and pre-defined outcomes at designated interim analyses.
         </p>
         <p>Given the potential for EPO to increase the risk of VTE, there are two planned interim
            safety analyses scheduled by the DSMC at six months, following 33% (n = 202) and 66%
            (n = 404) patient recruitment. The Haybittle-Peto criterion (|Z
            <sub>k</sub>| &gt; =3) for early stopping were applied at these first and second analyses. The final
            analyses at full recruitment will be little affected by these interim analyses (final
            critical value |Z
            <sub>3</sub>| &gt; =1.975 rather than 1.960) 
            <span tagx="abbrgrp">
               <span tagx="abbr">33</span>
            </span>.
         </p>
         <p>Consistent with other studies in critically ill patients, AEs already defined and
            reported as study outcomes (apart from death) will not be reported a second time as
            SAEs 
            <span tagx="abbrgrp">
               <span tagx="abbr">34</span>
            </span>.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>TBI is a common and devastating condition with few proven specific therapies available.
         The administration of EPO has the potential to reduce neurological damage and improve
         outcome, and is supported by a scientific rationale and laboratory data. The EPO-TBI
         design aims to maximise the ability to detect a beneficial effect, if one exists,
         between EPO and improved neurological function after TBI. Furthermore, our design
         features also aim to minimise the risk of VTE in this population, and to develop a
         prospective screening plan which will readily identify VTE events if they occur, allowing
         clinicians to provide appropriate treatment rapidly. EPO-TBI aims to provide definitive
         guidance for clinicians regarding the true efficacy and safety of EPO in the management
         of TBI.
      </p>
      <div id="">
         <div tagx="st">
            <h3>Trial status</h3>
         </div>
         <p>The trial commenced in May 2010 at The Alfred Hospital, Melbourne Australia. Two interim
            analyses were conducted with approval by the DSMC to continue the trial without alteration
            to the protocol. The target recruitment of 606 patients was achieved on 1 November
            2014, making final six-month outcomes available by May 2015.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Endnotes</h2>
      </div>
      <p>
         <sup>a</sup>Six sites have a minimum age of 15 years, 13 sites have a minimum age of 16 years
         and 10 sites have a minimum age of 18 years.
      </p>
      <p>
         <sup>b</sup>&lt;140 g/L at Johannes Gutenberg-Universtität, Mainz Germany, &lt;148 g/L for males and
         &lt;135 g/L for females at Royal Adelaide Hospital, Adelaide Australia.
      </p>
      <p>
         <sup>c</sup>Additional exclusion criteria at Johannes Gutenberg-Universtität, Mainz Germany. Uncontrolled
         hypertension parameters were more stringent (systolic blood pressure of &gt;160 mm Hg
         or diastolic blood pressure of &gt;90 mm Hg), morbid obesity, coronary artery disease,
         peripheral arterial occlusive disease, vascular disease of the carotid arteries, cerebrovascular
         disorders, recent stroke, contraindications against prophylaxis of DVT or an increased
         risk for DVT (for example, with additional trauma and /or operations, severe varicose
         veins, severe smokers, intake of oral contraceptives, infections and inflammation).
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>AE: Adverse event</p>
      <p>AIS: Abbreviated injury severity score</p>
      <p>ANZIC-RC: Australian and New Zealand Intensive Care Research Centre</p>
      <p>APACHE II: Acute Physiology and Chronic Health Evaluation II</p>
      <p>CI: Confidence interval</p>
      <p>DSMC: Data and Safety Monitoring Committee</p>
      <p>DVT: Deep venous thrombosis</p>
      <p>EPO: Erythropoietin</p>
      <p>EPO-TBI: Erythropoietin in Traumatic Brain Injury</p>
      <p>EQ-5D: EuroQol five dimensions</p>
      <p>GCS: Glasgow coma score</p>
      <p>GOSE: Extended Glasgow outcome scale</p>
      <p>Hb: Haemoglobin</p>
      <p>ISS: Injury severity score</p>
      <p>SF-12: Short Form-12</p>
      <p>TBI: Traumatic brain injury</p>
      <p>VTE: Venous thromboembolism</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>The authors declare that they have no competing interests.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>AN contributed to the original concept of the trial, contributed to acquisition of
         funding and drafted the manuscript; CF contributed to the original concept of the
         trial, drafted the manuscript and administration; LL manages the trial, contributed
         to the drafting of the manuscript and administration; JP drafted the statistical analysis
         component of the manuscript, contributed to the drafting of the manuscript and administration;
         DJC contributed to the original concept of the trial, acquired funding for the trial
         and contributed to the statistical analysis plan; SH is the principal investigator
         of the highest recruiting site, made significant contribution to the setup of the
         trial in the Kingdom of Saudi Arabia and contributed to the drafting of the manuscript;
         JD is the national principal investigator for France and contributed to the drafting
         of the manuscript; OH made a significant contribution to the setup of the trial in
         France and contributed to the drafting of the manuscript; MS contributed to the drafting
         of the manuscript and made a significant contribution to the setup of the trial in
         Finland; YA contributed to the drafting of the manuscript and is sub-investigator
         at the highest recruiting site; RB contributed to the original concept of the trial,
         was the leader in acquisition of funding and is the chief investigator. All authors
         read and approved the final manuscript.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Appendix 1: EPO-TBI unblinded project officer</h2>
      </div>
      <p>Belinda Howe, Australian and New Zealand Intensive Care Research Centre, Monash University,
         Melbourne, Australia.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Appendix 2: EPO-TBI outcome assessors</h2>
      </div>
      <p>Heather Waddy, Australian and New Zealand Intensive Care Research Centre, Monash University,
         Melbourne, Australia.
      </p>
      <p>Marwan Al Kishi, Department of Medicine, King Abdulaziz Medical City, Riyadh, Kingdom
         of Saudi Arabia.
      </p>
      <p>Sarah Kambire, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
      <p>Serge Camelo, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
      <p>Markus Skrifvars, Intensive Care Unit, Department of Anaesthesiology and Intensive
         Care Medicine, Helsinki University Hospital, Helsinki, Finland.
      </p>
      <p>Stepani Bendel, Intensive Care Unit, Division of Anaesthesiology and Intensive Care
         Medicine, Kuopio University Hospital, Kuopio, Finland.
      </p>
      <p>Carole Schilling, Royal College of Surgeons in Ireland, Education and Research Centre,
         Beaumont Hospital, Dublin, Ireland.
      </p>
      <p>Thomas Kerz, Department of Neurosurgery, Intensive Care Therapy Unit, Universitätsmedizin,
         Mainz, Germany.
      </p>
      <p>Lynnette Murray, Australian and New Zealand Intensive Care Research Centre, Monash
         University, Melbourne, Australia.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Appendix 3: EPO-TBI management committee</h2>
      </div>
      <p>Rinaldo Bellomo, Department of Intensive Care, Austin Health, Melbourne, Australia.</p>
      <p>Alistair Nichol, Department of Anaesthesia and Intensive Care Medicine, St Vincent’s
         University Hospital, Dublin, Ireland.
      </p>
      <p>Craig French, Department of Intensive Care, Western Health, Melbourne, Australia.</p>
      <p>D James Cooper, Department of Intensive Care Medicine, The Alfred, Melbourne, Australia.</p>
      <p>Olivier Huet, Intensive Care Unit, Department of Anesthesiology and Intensive Care
         Medicine, Centre Hospitalier Universitaire La Cavale Blanche, Brest, France.
      </p>
      <p>Lorraine Little, Australian and New Zealand Intensive Care Research Centre, Monash
         University, Melbourne, Australia.
      </p>
      <p>Anne Mak, Pharmacy Department, The Alfred, Melbourne, Australia.</p>
      <p>Ville Pettilä, Intensive care Units, Division of Anaesthesiology and Intensive Care
         Medicine, Helsinki University Central Hospital, Helsinki, Finland.
      </p>
      <p>Jeffrey Presneill, Department of Intensive Care, Mater Health Services, Brisbane,
         Australia.
      </p>
      <p>Shirley Vallance, Department of Intensive Care Medicine, The Alfred, Melbourne, Australia.</p>
      <p>Dinesh Varma, Department of Radiology, The Alfred, Melbourne, Australia.</p>
      <p>Judy Wills, Department of Radiology, The Alfred, Melbourne, Australia.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Appendix 4: EPO-TBI sites, principal investigator and research coordinator/s</h2>
      </div>
      <p>Auckland City Hospital, New Zealand: Colin McArthur, Yan Chen, Lynette Newby.</p>
      <p>Beaumont Hospital, Ireland: Criona Walshe, James O’Rourke, Carole Schilling.</p>
      <p>Canberra Hospital, Australia: Imogen Mitchell, Frank Van Haren, Helen Rodgers. Marta
         Kot
      </p>
      <p>Christchurch Hospital, New Zealand: Seton Henderson, Jan Mehrtens, Sascha Noble.</p>
      <p>Dunedin Hospital, New Zealand: Matthew Bailey, Robyn Hutchinson, Dawn France.</p>
      <p>Gold Coast University Hospital, Australia: Brent Richards, Mandy Tallott.</p>
      <p>Helsinki University Central Hospital, Finland: Markus Skrifvars, Heikki Vartiala,
         Marianne Eliasson.
      </p>
      <p>Hôpital Caremeau, France: Jean Yves Lefrant, Laurent Muller, Claire Roger, Christian
         Bengler, Pierre Barbaste.
      </p>
      <p>Hôpital Charles Nicolle, France: Benoit Veber, Marie Gilles-Baray, Pierre-Gildas Guitard,
         Helene Braud.
      </p>
      <p>Hôpital de Bicêtre, France: Jacques Duranteau, Anatole Harrois, Samy Figueiredo, Sophie
         Hamada.
      </p>
      <p>Hôpital Lariboisière, France: Didier Payen, Anne Claire Lukaszewicz, Charles Damoisel,
         Sarah Kambire.
      </p>
      <p>Hôpital Michallon, France: Jean François Payen, Pauline Manhes, Gilles Franconey,
         Perrine Boucheix.
      </p>
      <p>Johannes Gutenberg-Universtität, Germany: Thomas Kerz.</p>
      <p>John Hunter Hospital, Australia: Peter Harrigan, Miranda Hardie.</p>
      <p>King Abdulaziz Medical City, Kingdom of Saudi Arabia: Samir Haddad, Yaseen Arabi,
         Marwan Al Kishi, Ahmad Deeb, Shmeylan Al Harbi, Lolowa Al-Swaidan ,Turki Al Moammar,
         Juliet Lingling, Shella Caliwag, Hanie Richi.
      </p>
      <p>Kuopio University Hospital, Finland: Stepani Bendel, Sari Rahikainen, Mikko Myllymaki.</p>
      <p>Liverpool Hospital, Australia: Victor Tam, Sharon Micallef.</p>
      <p>Nepean Hospital, Australia: Louise Cole, Leonie Weisbrodt.</p>
      <p>Royal Adelaide Hospital, Australia: Richard Strickland, Justine Rivett, Sonya Kloeden,
         Stephanie O’Connor.
      </p>
      <p>Royal Hobart Hospital, Australia: David Cooper, Richard McAllister.</p>
      <p>Royal Melbourne Hospital, Australia: Nerina Harley, Deborah Barge, Elizabeth Moore,
         Andrea Jordan.
      </p>
      <p>Royal North Shore Hospital, Australia: Simon Finfer, Elizabeth Yarad, Simon Bird,
         Anne O’Connor.
      </p>
      <p>Royal Perth Hospital, Australia: Geoffrey Dobb, Jenny Chamberlain, Michelle Barr,
         Elizabeth Jenkinson.
      </p>
      <p>Royal Prince Alfred Hospital, Australia: David Gattas, Heidi Buhr, Debra Hutch, Megan
         Keir.
      </p>
      <p>St Vincent’s Hospital Sydney, Australia: Priya Nair, Claire Reynolds, Serena Knowles.</p>
      <p>The Alfred, Australia: D. James Cooper, Jasmin Board, Shirley Vallance, Phoebe McCracken.</p>
      <p>The Townsville Hospital, Australia: Geoffrey Gordon, Stephen Reeves.</p>
      <p>Wellington Regional Hospital, New Zealand: Richard Dinsdale, Lynn Andrews, Dianne
         Mackle, Sally Hurford.
      </p>
      <p>Westmead Hospital, Australia: Vineet Nayyar, Christina Whitehead, Jing Kong.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Appendix 5: EPO-TBI French management team</h2>
      </div>
      <p>Jacques Duranteau, National Principal Investigator, Service d’Anesthésie-Réanimation,
         Hôpitaux universitaires Paris Sud, Assistance Publique des Hôpitaux de Paris, Hôpital
         de Bicêtre, Le Kremlin-Bicêtre, France.
      </p>
      <p>Eric Vicaut, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
      <p>Philippe Gallula, Pole Promotion International, Assistance Publique-Hôpitaux de Paris,
         France.
      </p>
      <p>Vidhya Raghavan, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance
         Publique-Hôpitaux de Paris, France.
      </p>
      <p>Amel Chamam, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
      <p>Sarah Kambire, Unité de Recherche Clinique Lariboisière-Saint Louis, Assistance Publique-Hôpitaux
         de Paris, France.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Additional file</h2>
      </div>
      <div tagx="suppl">
         <div tagx="title">
            <p>Additional file 1:</p>
         </div>
         <div tagx="text">
            <p>
               <b>Project Title: Erythropoietin in traumatic brain injury.</b> List of participating centres and responsible ethics committees.
            </p>
         </div>
         <div tagx="file">
            <p>Click here for file</p>
         </div>
      </div>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgements</h2>
            </div>
            <p>EPO-TBI is funded by the Australian National Health and Medical Research Council Project
               (project grant ID 545901), and the Victorian Transport Accident Commission (project
               grant ID D162 - formerly, the Victorian Neurotrauma Initiative). The cost of Epoetin
               alfa was reimbursed to hospital pharmacy departments by using project grant funds.
               Neither funding agencies nor the manufacturer of Epoetin alfa had any role in the
               trial design, data collection or analysis.
            </p>
            <p>EPO-TBI trial is coordinated by the Australian and New Zealand Intensive Care Research
               Centre (ANZIC-RC), Monash University, Melbourne, Australia and endorsed by the Australian
               and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) and the
               Irish Critical Care Trials Group. The members of Management Committee are listed in
               Appendix 3
               
            </p>
            <p>The EPO-TBI trial sites, principal investigator(s) and research coordinator(s) are
               listed in Appendix 4.
            </p>
            <p>EPO-TBI is managed in France by the Unité de Recherche Clinique Lariboisière-Saint
               Louis, Assistance Publique-Hôpitaux de Paris. The EPO-TBI French management team is
               listed in Appendix 5.
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="note">Access Economics. The economic cost of spinal cord injury and traumatic brain injury
               in Australia. Report by Access Economics Pty Limited for The Victorian Neurotrauma
               Initiative
               <i>.</i> 2009; last access date 28 Jan 2015. 
               <a href="http://www.tac.vic.gov.au/about-the-tac/our-organisation/research/tac-neurotrauma-research/vni/the20economic20cost20of20spinal20cord20injury20and20traumatic20brain20injury20in20australia.pdf">http://www.tac.vic.gov.au/about-the-tac/our-organisation/research/tac-neurotrauma-research/vni/the20economic20cost20of20spinal20cord20injury20and20traumatic20brain20injury20in20australia.pdf</a>
               <i>.</i>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Pathophysiology of cerebral ischemia and brain trauma: similarities and differences</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bramlett</span>
                  <span tagx="fnm">HM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Dietrich</span>
                  <span tagx="fnm">WD</span>
               </li>
            </ul>
            <span tagx="source">J Cereb Blood Flow Metab</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">24</span>
            <span tagx="fpage">133</span>
            <span tagx="lpage">50</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/01.WCB.0000111614.19196.04</span>
                  <span tagx="pubid">14747740</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The role of erythropoietin in central and peripheral nerve injury</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Lykissas</span>
                  <span tagx="fnm">MG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Korompilias</span>
                  <span tagx="fnm">AV</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Vekris</span>
                  <span tagx="fnm">MD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mitsionis</span>
                  <span tagx="fnm">GI</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sakellariou</span>
                  <span tagx="fnm">E</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Beris</span>
                  <span tagx="fnm">AE</span>
               </li>
            </ul>
            <span tagx="source">Clin Neurol Neurosurg</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">109</span>
            <span tagx="fpage">639</span>
            <span tagx="lpage">44</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.clineuro.2007.05.013</span>
                  <span tagx="pubid">17624659</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Science review: recombinant human erythropoietin in critical illness: a role beyond
                  anemia?
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Coleman</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brines</span>
                  <span tagx="fnm">M</span>
               </li>
            </ul>
            <span tagx="source">Crit Care</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">8</span>
            <span tagx="fpage">337</span>
            <span tagx="lpage">41</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/cc2897</span>
                  <span tagx="pubid">15469595</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal
                  apoptosis and inflammation in a rodent model of experimental closed head injury
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Yatsiv</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Grigoriadis</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Simeonidou</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Stahel</span>
                  <span tagx="fnm">PF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schmidt</span>
                  <span tagx="fnm">OI</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Alexandrovitch</span>
                  <span tagx="fnm">AG</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">FASEB J</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">19</span>
            <span tagx="fpage">1701</span>
            <span tagx="lpage">3</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">16099948</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic
                  brain injury
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Lu</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mahmood</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Qu</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Goussev</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schallert</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Chopp</span>
                  <span tagx="fnm">M</span>
               </li>
            </ul>
            <span tagx="source">J Neurotrauma</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">22</span>
            <span tagx="fpage">1011</span>
            <span tagx="lpage">7</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1089/neu.2005.22.1011</span>
                  <span tagx="pubid">16156716</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Efficacy of recombinant human erythropoietin in critically ill patients: a randomized
                  controlled trial
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Corwin</span>
                  <span tagx="fnm">HL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gettinger</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pearl</span>
                  <span tagx="fnm">RG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fink</span>
                  <span tagx="fnm">MP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Levy</span>
                  <span tagx="fnm">MM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shapiro</span>
                  <span tagx="fnm">MJ</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">JAMA</span>
            <span tagx="pubdate">2002</span>
            <span tagx="volume">288</span>
            <span tagx="fpage">2827</span>
            <span tagx="lpage">35</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1001/jama.288.22.2827</span>
                  <span tagx="pubid">12472324</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Efficacy and safety of epoetin alfa in critically ill patients</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Corwin</span>
                  <span tagx="fnm">HL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gettinger</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fabian</span>
                  <span tagx="fnm">TC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">May</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pearl</span>
                  <span tagx="fnm">RG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Heard</span>
                  <span tagx="fnm">S</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">N Engl J Med</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">357</span>
            <span tagx="fpage">965</span>
            <span tagx="lpage">76</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1056/NEJMoa071533</span>
                  <span tagx="pubid">17804841</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effect of erythropoietin on Glasgow Coma Scale and Glasgow Outcome Sale in patient
                  with diffuse axonal injury
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Abrishamkar</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Safavi</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Honarmand</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">J Res Med Sci</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">17</span>
            <span tagx="fpage">51</span>
            <span tagx="lpage">6</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">23248657</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Erythropoiesis-stimulating agent administration and survival after severe traumatic
                  brain injury: a prospective study
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Talving</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lustenberger</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Inaba</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lam</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mohseni</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Chan</span>
                  <span tagx="fnm">L</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Arch Surg</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">147</span>
            <span tagx="fpage">251</span>
            <span tagx="lpage">5</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1001/archsurg.2011.1838</span>
                  <span tagx="pubid">22430906</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Erythropoietin or darbepoetin for patients with cancer</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Tonia</span>
                  <span tagx="fnm">T</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Mettler</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Robert</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schwarzer</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Seidenfeld</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Weingart</span>
                  <span tagx="fnm">O</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Cochrane Database Syst Rev</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">12</span>
            <span tagx="fpage">CD003407</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">23235597</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Correction of anemia with epoetin alfa in chronic kidney disease</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Singh</span>
                  <span tagx="fnm">AK</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Szczech</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tang</span>
                  <span tagx="fnm">KL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Barnhart</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sapp</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wolfson</span>
                  <span tagx="fnm">M</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">N Engl J Med</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">355</span>
            <span tagx="fpage">2085</span>
            <span tagx="lpage">98</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1056/NEJMoa065485</span>
                  <span tagx="pubid">17108343</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Analyzing outcome of treatment of severe head injury: a review and update on advancing
                  the use of the Glasgow Outcome Scale
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Teasdale</span>
                  <span tagx="fnm">GM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pettigrew</span>
                  <span tagx="fnm">LE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wilson</span>
                  <span tagx="fnm">JT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Murray</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jennett</span>
                  <span tagx="fnm">B</span>
               </li>
            </ul>
            <span tagx="source">J Neurotrauma</span>
            <span tagx="pubdate">1998</span>
            <span tagx="volume">15</span>
            <span tagx="fpage">587</span>
            <span tagx="lpage">97</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1089/neu.1998.15.587</span>
                  <span tagx="pubid">9726258</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of
                  reliability and validity
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ware</span>
                  <span tagx="fnm">J</span>
                  <div tagx="suf">Jr</div>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kosinski</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Keller</span>
                  <span tagx="fnm">SD</span>
               </li>
            </ul>
            <span tagx="source">Med Care</span>
            <span tagx="pubdate">1996</span>
            <span tagx="volume">34</span>
            <span tagx="fpage">220</span>
            <span tagx="lpage">33</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/00005650-199603000-00003</span>
                  <span tagx="pubid">8628042</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">EuroQol Group. EQ-5D™ instrument for describing and valuing health-related quality
               of life. 2014. Last access date 28 Jan 2015. 
               <a href="http://www.euroqol.org/home.html">http://www.euroqol.org/home.html</a>.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Cook</span>
                  <span tagx="fnm">DJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rocker</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Meade</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guyatt</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Geerts</span>
                  <span tagx="fnm">W</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Anderson</span>
                  <span tagx="fnm">D</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Crit Care</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">20</span>
            <span tagx="fpage">364</span>
            <span tagx="lpage">72</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.jcrc.2005.09.010</span>
                  <span tagx="pubid">16310609</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Anemia and blood transfusion in critically ill patients</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Vincent</span>
                  <span tagx="fnm">JL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Baron</span>
                  <span tagx="fnm">JF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Reinhart</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gattinoni</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Thijs</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Webb</span>
                  <span tagx="fnm">A</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">JAMA</span>
            <span tagx="pubdate">2002</span>
            <span tagx="volume">288</span>
            <span tagx="fpage">1499</span>
            <span tagx="lpage">507</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1001/jama.288.12.1499</span>
                  <span tagx="pubid">12243637</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The CRIT Study: anemia and blood transfusion in the critically ill - current clinical
                  practice in the United States
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Corwin</span>
                  <span tagx="fnm">HL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gettinger</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pearl</span>
                  <span tagx="fnm">RG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Fink</span>
                  <span tagx="fnm">MP</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Levy</span>
                  <span tagx="fnm">MM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Abraham</span>
                  <span tagx="fnm">E</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Crit Care Med</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">32</span>
            <span tagx="fpage">39</span>
            <span tagx="lpage">52</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/01.CCM.0000104112.34142.79</span>
                  <span tagx="pubid">14707558</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Guidelines for the management of severe traumatic brain injury</p>
            </div>
            <ul tagx="insg">
               <li tagx="ins">
                  <p>Brain Trauma Foundation</p>
               </li>
            </ul>
            <span tagx="source">J Neurotrauma</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">24</span>
            <span tagx="issue">Suppl 1</span>
            <span tagx="fpage">S1</span>
            <span tagx="lpage">106</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The diagnosis of head injury requires a classification based on computed axial tomography</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Marshall</span>
                  <span tagx="fnm">LF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Marshall</span>
                  <span tagx="fnm">SB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Klauber</span>
                  <span tagx="fnm">MR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Van Berkum</span>
                  <span tagx="fnm">CM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Eisenberg</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jane</span>
                  <span tagx="fnm">JA</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Neurotrauma</span>
            <span tagx="pubdate">1992</span>
            <span tagx="volume">9</span>
            <span tagx="issue">Suppl 1</span>
            <span tagx="fpage">S287</span>
            <span tagx="lpage">92</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">1588618</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome
                  Scale: guidelines for their use
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wilson</span>
                  <span tagx="fnm">JT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pettigrew</span>
                  <span tagx="fnm">LE</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Teasdale</span>
                  <span tagx="fnm">GM</span>
               </li>
            </ul>
            <span tagx="source">J Neurotrauma</span>
            <span tagx="pubdate">1998</span>
            <span tagx="volume">15</span>
            <span tagx="fpage">573</span>
            <span tagx="lpage">85</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1089/neu.1998.15.573</span>
                  <span tagx="pubid">9726257</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Post-randomisation exclusions: the intention to treat principle and excluding patients
                  from analysis
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Fergusson</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Aaron</span>
                  <span tagx="fnm">SD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guyatt</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hebert</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">BMJ</span>
            <span tagx="pubdate">2002</span>
            <span tagx="volume">325</span>
            <span tagx="fpage">652</span>
            <span tagx="lpage">4</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/bmj.325.7365.652</span>
                  <span tagx="pubid">12242181</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Perner</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Haase</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guttormsen</span>
                  <span tagx="fnm">AB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tenhunen</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Klemenzson</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Aneman</span>
                  <span tagx="fnm">A</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">N Engl J Med</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">367</span>
            <span tagx="fpage">124</span>
            <span tagx="lpage">34</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1056/NEJMoa1204242</span>
                  <span tagx="pubid">22738085</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Quality of life after traumatic brain injury: a review of research approaches and
                  findings
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Dijkers</span>
                  <span tagx="fnm">MP</span>
               </li>
            </ul>
            <span tagx="source">Arch Phys Med Rehabil</span>
            <span tagx="pubdate">2004</span>
            <span tagx="volume">85</span>
            <span tagx="fpage">S21</span>
            <span tagx="lpage">35</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.apmr.2003.08.119</span>
                  <span tagx="pubid">15083419</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Quality of life in patients with traumatic brain injury-basic issues, assessment and
                  recommendations
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bullinger</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Azouvi</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Brooks</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Basso</span>
                  <span tagx="fnm">A</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Christensen</span>
                  <span tagx="fnm">AL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gobiet</span>
                  <span tagx="fnm">W</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Restor Neurol Neurosci</span>
            <span tagx="pubdate">2002</span>
            <span tagx="volume">20</span>
            <span tagx="fpage">111</span>
            <span tagx="lpage">24</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">12454360</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New
                  Zealand
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Myburgh</span>
                  <span tagx="fnm">JA</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cooper</span>
                  <span tagx="fnm">DJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Finfer</span>
                  <span tagx="fnm">SR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Venkatesh</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jones</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Higgins</span>
                  <span tagx="fnm">A</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Trauma</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">64</span>
            <span tagx="fpage">854</span>
            <span tagx="lpage">62</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/TA.0b013e3180340e77</span>
                  <span tagx="pubid">18404048</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Saline or albumin for fluid resuscitation in patients with traumatic brain injury</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Myburgh</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Cooper</span>
                  <span tagx="fnm">DJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Finfer</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bellomo</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Norton</span>
                  <span tagx="fnm">R</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bishop</span>
                  <span tagx="fnm">N</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">N Engl J Med</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">357</span>
            <span tagx="fpage">874</span>
            <span tagx="lpage">84</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1056/NEJMoa067514</span>
                  <span tagx="pubid">17761591</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hosmer</span>
                  <span tagx="fnm">DW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lemeshow</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sturdivant</span>
                  <span tagx="fnm">RX</span>
               </li>
            </ul>
            <span tagx="source">Applied logistic regression</span>
            <div tagx="publisher">Wiley, Hoboken, New Jersey</div>
            <span tagx="pubdate">2013</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The added value of ordinal analysis in clinical trials: an example in traumatic brain
                  injury
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Roozenbeek</span>
                  <span tagx="fnm">B</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lingsma</span>
                  <span tagx="fnm">HF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Perel</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Edwards</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Roberts</span>
                  <span tagx="fnm">I</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Murray</span>
                  <span tagx="fnm">GD</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Crit Care</span>
            <span tagx="pubdate">2011</span>
            <span tagx="volume">15</span>
            <span tagx="fpage">R127</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1186/cc10240</span>
                  <span tagx="pubid">21586148</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Cummings P. Re: converting an adjusted odds ratio to a risk ratio will produce biased
               estimates. BMJ. 2014; 348:f7450/rr/684808.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Converting an odds ratio to a range of plausible relative risks for better communication
                  of research findings
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Grant</span>
                  <span tagx="fnm">RL</span>
               </li>
            </ul>
            <span tagx="source">BMJ</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">348</span>
            <span tagx="fpage">f7450</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/bmj.f7450</span>
                  <span tagx="pubid">24464277</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Computing adjusted risk ratios and risk differences in Stata</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Norton</span>
                  <span tagx="fnm">EC</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Miller</span>
                  <span tagx="fnm">MM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kleinman</span>
                  <span tagx="fnm">LC</span>
               </li>
            </ul>
            <span tagx="source">Stata J</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">13</span>
            <span tagx="fpage">492</span>
            <span tagx="lpage">509</span>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Jennison</span>
                  <span tagx="fnm">C</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Turnbull</span>
                  <span tagx="fnm">BW</span>
               </li>
            </ul>
            <span tagx="source">Group sequential methods with applications to clinical trials</span>
            <div tagx="publisher">Chapman &amp; Hall/CRC, Boca Raton, Florida</div>
            <span tagx="pubdate">2000</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Serious adverse events in academic critical care research</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Cook</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Lauzier</span>
                  <span tagx="fnm">F</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Rocha</span>
                  <span tagx="fnm">MG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sayles</span>
                  <span tagx="fnm">MJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Finfer</span>
                  <span tagx="fnm">S</span>
               </li>
            </ul>
            <span tagx="source">CMAJ</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">178</span>
            <span tagx="fpage">1181</span>
            <span tagx="lpage">4</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1503/cmaj.071366</span>
                  <span tagx="pubid">18427095</span>
               </div>
            </div>
         </div>
      </div>
   </div>
</html>